Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
By: blendininn
03 Jun 2006, 04:57 PM EDT
Msg. 37672 of 37683
(This msg. is a reply to 37670 by blendininn.)
Jump to msg. #
Steve Berg has personally seen the results of Nicosan treatment & says it is "truly amazing" how effective this drug is for those suffering from SCD..still pumped from yesterday!
(Voluntary Disclosure: Position- Long; ST Rating- Strong Buy; LT Rating- Strong Buy)
NITE keeps backing up, .015
Xechem has indicated that it would like to launch the drug in Nigeria by early July 2006, and shortly thereafter to embark on the clinical trials in the US hospitals for FDA approval through the Investigational New Drug (IND) Application for sale of the drug in the United States.
Morning Stock Focus List For Thursday, June 01, 2006: Closing on Loan to Facilitate Expansion!
NOTE TO EDITORS: The Following Is an Investment Opinion Being Issued by Peter Antipatis of Capital Research Group Inc.
WESTON, FL -- (MARKET WIRE) -- 06/01/2006 -- TheSUBWAY.com names the following stocks to its Stock Focus List: Xechem International Inc. (OTCBB: XKEM), Novell, Inc. (NASDAQ: NOVL), Rambus Inc. (NASDAQ: RMBS), Cell Therapeutics, Inc. (NASDAQ: CTIC
Tommorrow volume will tell more of the story,
someone on allstocks just posted this,
But on a lighter side I just got off the phone with Steve Burg.
Of course there is nothing new he can say about a pr and when all he said was it should be soon. All the information is in and they are ready to provide any that they have.
He also said that the drug works and has been used under labrotory conditions snice 1994
Also he said that the bulk of the manufacturing plant has been built not 100% but enough to start if they had to
It is just a waiting game now and approval in his opinion is just making sure the nigerian Gov. is sure the drug will not harm there people and there is no bad intent
One name, MARIO, and I ain't talking no video game.
What the f*** is Mario doing with ONYY? Anyone know?
How long hs this site been up?
http://www.ctglf.com/
International Next Generation Network Provider Interoute Selects Sonus Networks for Multi-Million Dollar Network Expansion
May 10, 2006 07:25:32 (ET)
SWINDON, England, May 10, 2006 /PRNewswire-FirstCall via COMTEX/ -- Sonus Networks, Inc. (SONS, Trade), a leading supplier of service provider Voice over IP (VoIP) infrastructure solutions, announced today that Interoute, owner and operator of one of Europe's most advanced telecommunications networks, has selected Sonus Networks' IMS (IP Multimedia Subsystem)-ready network infrastructure solutions to support the multimillion dollar expansion of its IP-based voice network into several major markets, including Madrid, Spain and Milan, Italy. The Sonus solution offers Interoute the authentication and security features necessary to support its carrier-class Virtual Voice Network (VVN) service and Arena, Interoute's commission-free voice exchange, which gives carriers the ability to exchange traffic securely and flexibly with other operators around the world. Sonus' IMS-ready, standards-based platform was selected because it provides Interoute with the scalability and reliability necessary to meet the growing demand for the company's enhanced voice services.
"For years Sonus and Interoute have partnered to develop one of Europe's most sophisticated VoIP networks. Interoute has been a pioneer in the rollout of high value IP-based services, such as iSip and Arena, and continues to invest in its Sonus-based network to differentiate itself as one of the premier providers of VoIP services in the region," said Hassan Ahmed, chairman and CEO, Sonus Networks. "As Interoute further extends its presence in cities throughout Europe, Sonus is uniquely positioned to help them meet their growth objectives and support the increasing amount of traffic being carried on their network."
"We selected the Sonus platform because, from day one, we recognized the flexibility that its distributed, standards-based architecture would deliver," said Matthew Finnie, CTO Interoute. "The Sonus platform utilizes sound engineering principles fundamentally in line with the emerging IMS standards, which enables the development of standards-based services such as enhanced content aggregation and delivery. A standards-based architecture is essential for the shared infrastructure products that Interoute offers to our customers."
Interoute has been a Sonus customer since 2002 and has deployed the complete Sonus architecture, including the GSX9000(TM) Open Services Switch, the PSX(TM) Call Routing Server and the Sonus Insight(TM) Management System in cities across Europe and North America.
About Interoute
Interoute is Europe's fastest growing telecoms provider and owner operator of the continent's most advanced and densely connected voice and data network. It delivers intelligent, customer-controlled network services to a diverse range of businesses including carriers, mobile operators, service providers, enterprise customers and governments. With established operations throughout mainland Europe and North America, Interoute also owns and operates long-haul and dense city networks throughout Europe's major business centers.
About Sonus Networks
Sonus Networks, Inc. is a leading provider of Voice over IP (VoIP) infrastructure solutions for wireline and wireless service providers. With its comprehensive IP Multimedia Subsystem (IMS) solution, Sonus addresses the full range of carrier applications, including residential and business voice services, wireless voice and multimedia, trunking and tandem switching, carrier interconnection and enhanced services. Sonus' voice infrastructure solutions are deployed in service provider networks worldwide. Founded in 1997, Sonus is headquartered in Chelmsford, Massachusetts. Additional information on Sonus is available at http://www.sonusnet.com.
This release may contain forward-looking statements regarding future events that involve risks and uncertainties. Readers are cautioned that these forward-looking statements are only predictions and may differ materially from actual future events or results. Readers are referred to the "Risk Factors" section of Sonus' Annual Report on Form 10-K, dated March 14, 2006 and Quarterly Report on Form 10-Q, dated May 8, 2006, both filed with the SEC, which identify important risk factors that could cause actual results to differ from those contained in the forward-looking statements. Risk factors include among others: the impact of material weaknesses in our disclosure controls and procedures and our internal control over financial reporting on our ability to report our financial results timely and accurately; the unpredictability of our quarterly financial results; risks associated with our international expansion and growth; consolidation in the telecommunications industry; and potential costs resulting from pending securities litigation against the company. Any forward-looking statements represent Sonus' views only as of today and should not be relied upon as representing Sonus' views as of any subsequent date. While Sonus may elect to update forward-looking statements at some point, Sonus specifically disclaims any obligation to do so.
Sonus is a registered trademark of Sonus Networks, Inc. Sonus GSX9000 Open Services Switch, PSX Call Routing Server, SGX Signaling Gateway, and the Sonus Insight Management System are trademarks of Sonus Networks, Inc. All other company and product names may be trademarks of the respective companies with which they are associated.
For more information, please contact:
Investor Relations: Media Relations: Media Relations EMEA:
Jocelyn Philbrook Sarah McAuley Tom Cheesewright
+1 978-614-8672 +1 212-699-1836 +44 1628 628080
jphilbrook@sonusnet.com smcauley@sonusnet.com TomC@Noiseworks.com
SOURCE Sonus Networks, Inc.
International Next Generation Network Provider Interoute Selects Sonus Networks for Multi-Million Dollar Network Expansion
May 10, 2006 07:25:32 (ET)
SWINDON, England, May 10, 2006 /PRNewswire-FirstCall via COMTEX/ -- Sonus Networks, Inc. (SONS, Trade), a leading supplier of service provider Voice over IP (VoIP) infrastructure solutions, announced today that Interoute, owner and operator of one of Europe's most advanced telecommunications networks, has selected Sonus Networks' IMS (IP Multimedia Subsystem)-ready network infrastructure solutions to support the multimillion dollar expansion of its IP-based voice network into several major markets, including Madrid, Spain and Milan, Italy. The Sonus solution offers Interoute the authentication and security features necessary to support its carrier-class Virtual Voice Network (VVN) service and Arena, Interoute's commission-free voice exchange, which gives carriers the ability to exchange traffic securely and flexibly with other operators around the world. Sonus' IMS-ready, standards-based platform was selected because it provides Interoute with the scalability and reliability necessary to meet the growing demand for the company's enhanced voice services.
"For years Sonus and Interoute have partnered to develop one of Europe's most sophisticated VoIP networks. Interoute has been a pioneer in the rollout of high value IP-based services, such as iSip and Arena, and continues to invest in its Sonus-based network to differentiate itself as one of the premier providers of VoIP services in the region," said Hassan Ahmed, chairman and CEO, Sonus Networks. "As Interoute further extends its presence in cities throughout Europe, Sonus is uniquely positioned to help them meet their growth objectives and support the increasing amount of traffic being carried on their network."
"We selected the Sonus platform because, from day one, we recognized the flexibility that its distributed, standards-based architecture would deliver," said Matthew Finnie, CTO Interoute. "The Sonus platform utilizes sound engineering principles fundamentally in line with the emerging IMS standards, which enables the development of standards-based services such as enhanced content aggregation and delivery. A standards-based architecture is essential for the shared infrastructure products that Interoute offers to our customers."
Interoute has been a Sonus customer since 2002 and has deployed the complete Sonus architecture, including the GSX9000(TM) Open Services Switch, the PSX(TM) Call Routing Server and the Sonus Insight(TM) Management System in cities across Europe and North America.
About Interoute
Interoute is Europe's fastest growing telecoms provider and owner operator of the continent's most advanced and densely connected voice and data network. It delivers intelligent, customer-controlled network services to a diverse range of businesses including carriers, mobile operators, service providers, enterprise customers and governments. With established operations throughout mainland Europe and North America, Interoute also owns and operates long-haul and dense city networks throughout Europe's major business centers.
About Sonus Networks
Sonus Networks, Inc. is a leading provider of Voice over IP (VoIP) infrastructure solutions for wireline and wireless service providers. With its comprehensive IP Multimedia Subsystem (IMS) solution, Sonus addresses the full range of carrier applications, including residential and business voice services, wireless voice and multimedia, trunking and tandem switching, carrier interconnection and enhanced services. Sonus' voice infrastructure solutions are deployed in service provider networks worldwide. Founded in 1997, Sonus is headquartered in Chelmsford, Massachusetts. Additional information on Sonus is available at http://www.sonusnet.com.
This release may contain forward-looking statements regarding future events that involve risks and uncertainties. Readers are cautioned that these forward-looking statements are only predictions and may differ materially from actual future events or results. Readers are referred to the "Risk Factors" section of Sonus' Annual Report on Form 10-K, dated March 14, 2006 and Quarterly Report on Form 10-Q, dated May 8, 2006, both filed with the SEC, which identify important risk factors that could cause actual results to differ from those contained in the forward-looking statements. Risk factors include among others: the impact of material weaknesses in our disclosure controls and procedures and our internal control over financial reporting on our ability to report our financial results timely and accurately; the unpredictability of our quarterly financial results; risks associated with our international expansion and growth; consolidation in the telecommunications industry; and potential costs resulting from pending securities litigation against the company. Any forward-looking statements represent Sonus' views only as of today and should not be relied upon as representing Sonus' views as of any subsequent date. While Sonus may elect to update forward-looking statements at some point, Sonus specifically disclaims any obligation to do so.
Sonus is a registered trademark of Sonus Networks, Inc. Sonus GSX9000 Open Services Switch, PSX Call Routing Server, SGX Signaling Gateway, and the Sonus Insight Management System are trademarks of Sonus Networks, Inc. All other company and product names may be trademarks of the respective companies with which they are associated.
For more information, please contact:
Investor Relations: Media Relations: Media Relations EMEA:
Jocelyn Philbrook Sarah McAuley Tom Cheesewright
+1 978-614-8672 +1 212-699-1836 +44 1628 628080
jphilbrook@sonusnet.com smcauley@sonusnet.com TomC@Noiseworks.com
SOURCE Sonus Networks, Inc.
International Next Generation Network Provider Interoute Selects Sonus Networks for Multi-Million Dollar Network Expansion
May 10, 2006 07:25:32 (ET)
SWINDON, England, May 10, 2006 /PRNewswire-FirstCall via COMTEX/ -- Sonus Networks, Inc. (SONS, Trade), a leading supplier of service provider Voice over IP (VoIP) infrastructure solutions, announced today that Interoute, owner and operator of one of Europe's most advanced telecommunications networks, has selected Sonus Networks' IMS (IP Multimedia Subsystem)-ready network infrastructure solutions to support the multimillion dollar expansion of its IP-based voice network into several major markets, including Madrid, Spain and Milan, Italy. The Sonus solution offers Interoute the authentication and security features necessary to support its carrier-class Virtual Voice Network (VVN) service and Arena, Interoute's commission-free voice exchange, which gives carriers the ability to exchange traffic securely and flexibly with other operators around the world. Sonus' IMS-ready, standards-based platform was selected because it provides Interoute with the scalability and reliability necessary to meet the growing demand for the company's enhanced voice services.
"For years Sonus and Interoute have partnered to develop one of Europe's most sophisticated VoIP networks. Interoute has been a pioneer in the rollout of high value IP-based services, such as iSip and Arena, and continues to invest in its Sonus-based network to differentiate itself as one of the premier providers of VoIP services in the region," said Hassan Ahmed, chairman and CEO, Sonus Networks. "As Interoute further extends its presence in cities throughout Europe, Sonus is uniquely positioned to help them meet their growth objectives and support the increasing amount of traffic being carried on their network."
"We selected the Sonus platform because, from day one, we recognized the flexibility that its distributed, standards-based architecture would deliver," said Matthew Finnie, CTO Interoute. "The Sonus platform utilizes sound engineering principles fundamentally in line with the emerging IMS standards, which enables the development of standards-based services such as enhanced content aggregation and delivery. A standards-based architecture is essential for the shared infrastructure products that Interoute offers to our customers."
Interoute has been a Sonus customer since 2002 and has deployed the complete Sonus architecture, including the GSX9000(TM) Open Services Switch, the PSX(TM) Call Routing Server and the Sonus Insight(TM) Management System in cities across Europe and North America.
About Interoute
Interoute is Europe's fastest growing telecoms provider and owner operator of the continent's most advanced and densely connected voice and data network. It delivers intelligent, customer-controlled network services to a diverse range of businesses including carriers, mobile operators, service providers, enterprise customers and governments. With established operations throughout mainland Europe and North America, Interoute also owns and operates long-haul and dense city networks throughout Europe's major business centers.
About Sonus Networks
Sonus Networks, Inc. is a leading provider of Voice over IP (VoIP) infrastructure solutions for wireline and wireless service providers. With its comprehensive IP Multimedia Subsystem (IMS) solution, Sonus addresses the full range of carrier applications, including residential and business voice services, wireless voice and multimedia, trunking and tandem switching, carrier interconnection and enhanced services. Sonus' voice infrastructure solutions are deployed in service provider networks worldwide. Founded in 1997, Sonus is headquartered in Chelmsford, Massachusetts. Additional information on Sonus is available at http://www.sonusnet.com.
This release may contain forward-looking statements regarding future events that involve risks and uncertainties. Readers are cautioned that these forward-looking statements are only predictions and may differ materially from actual future events or results. Readers are referred to the "Risk Factors" section of Sonus' Annual Report on Form 10-K, dated March 14, 2006 and Quarterly Report on Form 10-Q, dated May 8, 2006, both filed with the SEC, which identify important risk factors that could cause actual results to differ from those contained in the forward-looking statements. Risk factors include among others: the impact of material weaknesses in our disclosure controls and procedures and our internal control over financial reporting on our ability to report our financial results timely and accurately; the unpredictability of our quarterly financial results; risks associated with our international expansion and growth; consolidation in the telecommunications industry; and potential costs resulting from pending securities litigation against the company. Any forward-looking statements represent Sonus' views only as of today and should not be relied upon as representing Sonus' views as of any subsequent date. While Sonus may elect to update forward-looking statements at some point, Sonus specifically disclaims any obligation to do so.
Sonus is a registered trademark of Sonus Networks, Inc. Sonus GSX9000 Open Services Switch, PSX Call Routing Server, SGX Signaling Gateway, and the Sonus Insight Management System are trademarks of Sonus Networks, Inc. All other company and product names may be trademarks of the respective companies with which they are associated.
For more information, please contact:
Investor Relations: Media Relations: Media Relations EMEA:
Jocelyn Philbrook Sarah McAuley Tom Cheesewright
+1 978-614-8672 +1 212-699-1836 +44 1628 628080
jphilbrook@sonusnet.com smcauley@sonusnet.com TomC@Noiseworks.com
SOURCE Sonus Networks, Inc.
International Next Generation Network Provider Interoute Selects Sonus Networks for Multi-Million Dollar Network Expansion
May 10, 2006 07:25:32 (ET)
SWINDON, England, May 10, 2006 /PRNewswire-FirstCall via COMTEX/ -- Sonus Networks, Inc. (SONS, Trade), a leading supplier of service provider Voice over IP (VoIP) infrastructure solutions, announced today that Interoute, owner and operator of one of Europe's most advanced telecommunications networks, has selected Sonus Networks' IMS (IP Multimedia Subsystem)-ready network infrastructure solutions to support the multimillion dollar expansion of its IP-based voice network into several major markets, including Madrid, Spain and Milan, Italy. The Sonus solution offers Interoute the authentication and security features necessary to support its carrier-class Virtual Voice Network (VVN) service and Arena, Interoute's commission-free voice exchange, which gives carriers the ability to exchange traffic securely and flexibly with other operators around the world. Sonus' IMS-ready, standards-based platform was selected because it provides Interoute with the scalability and reliability necessary to meet the growing demand for the company's enhanced voice services.
"For years Sonus and Interoute have partnered to develop one of Europe's most sophisticated VoIP networks. Interoute has been a pioneer in the rollout of high value IP-based services, such as iSip and Arena, and continues to invest in its Sonus-based network to differentiate itself as one of the premier providers of VoIP services in the region," said Hassan Ahmed, chairman and CEO, Sonus Networks. "As Interoute further extends its presence in cities throughout Europe, Sonus is uniquely positioned to help them meet their growth objectives and support the increasing amount of traffic being carried on their network."
"We selected the Sonus platform because, from day one, we recognized the flexibility that its distributed, standards-based architecture would deliver," said Matthew Finnie, CTO Interoute. "The Sonus platform utilizes sound engineering principles fundamentally in line with the emerging IMS standards, which enables the development of standards-based services such as enhanced content aggregation and delivery. A standards-based architecture is essential for the shared infrastructure products that Interoute offers to our customers."
Interoute has been a Sonus customer since 2002 and has deployed the complete Sonus architecture, including the GSX9000(TM) Open Services Switch, the PSX(TM) Call Routing Server and the Sonus Insight(TM) Management System in cities across Europe and North America.
About Interoute
Interoute is Europe's fastest growing telecoms provider and owner operator of the continent's most advanced and densely connected voice and data network. It delivers intelligent, customer-controlled network services to a diverse range of businesses including carriers, mobile operators, service providers, enterprise customers and governments. With established operations throughout mainland Europe and North America, Interoute also owns and operates long-haul and dense city networks throughout Europe's major business centers.
About Sonus Networks
Sonus Networks, Inc. is a leading provider of Voice over IP (VoIP) infrastructure solutions for wireline and wireless service providers. With its comprehensive IP Multimedia Subsystem (IMS) solution, Sonus addresses the full range of carrier applications, including residential and business voice services, wireless voice and multimedia, trunking and tandem switching, carrier interconnection and enhanced services. Sonus' voice infrastructure solutions are deployed in service provider networks worldwide. Founded in 1997, Sonus is headquartered in Chelmsford, Massachusetts. Additional information on Sonus is available at http://www.sonusnet.com.
This release may contain forward-looking statements regarding future events that involve risks and uncertainties. Readers are cautioned that these forward-looking statements are only predictions and may differ materially from actual future events or results. Readers are referred to the "Risk Factors" section of Sonus' Annual Report on Form 10-K, dated March 14, 2006 and Quarterly Report on Form 10-Q, dated May 8, 2006, both filed with the SEC, which identify important risk factors that could cause actual results to differ from those contained in the forward-looking statements. Risk factors include among others: the impact of material weaknesses in our disclosure controls and procedures and our internal control over financial reporting on our ability to report our financial results timely and accurately; the unpredictability of our quarterly financial results; risks associated with our international expansion and growth; consolidation in the telecommunications industry; and potential costs resulting from pending securities litigation against the company. Any forward-looking statements represent Sonus' views only as of today and should not be relied upon as representing Sonus' views as of any subsequent date. While Sonus may elect to update forward-looking statements at some point, Sonus specifically disclaims any obligation to do so.
Sonus is a registered trademark of Sonus Networks, Inc. Sonus GSX9000 Open Services Switch, PSX Call Routing Server, SGX Signaling Gateway, and the Sonus Insight Management System are trademarks of Sonus Networks, Inc. All other company and product names may be trademarks of the respective companies with which they are associated.
For more information, please contact:
Investor Relations: Media Relations: Media Relations EMEA:
Jocelyn Philbrook Sarah McAuley Tom Cheesewright
+1 978-614-8672 +1 212-699-1836 +44 1628 628080
jphilbrook@sonusnet.com smcauley@sonusnet.com TomC@Noiseworks.com
SOURCE Sonus Networks, Inc.
MM's run RB
Here is what another HERBAL company is doing (Sunwin International Neutraceuticals, Inc. (OTC BB: SUWN), an industry leader in the production and distribution of Chinese herbs, veterinary medicines and low calorie sweetener (Stevia) in China, announced today that the company's Stevia production at their newly constructed facility has reached 22 to 25 tons per month or 260 to 300 tons per year following a major renovation effort commenced in 2005.) XKEM will be here too:
http://www.investorshub.com/boards/quotes.asp?ticker=suwn
Time will tell my friend.
Cyberlux Joins forces with Collier County Emergency
Management Officials for Emergency Preparation Education
Cyberlux’s EverOn multi-purpose Emergency light chosen as a Valuable
Resource in Hurricane and Tornado Preparedness
RESEARCH TRIANGLE PARK, N.C., (April 26, 2006) – Cyberlux Corporation
(OTCBB: CYBL) a leading provider of LED lighting solutions, announced today that the
company has partnered with Emergency Management officials in Collier County, Florida
to educate the public on emergency preparation for the hurricane season. Cyberlux’s
EverOn Multi-Purpose Emergency Light is a component of Collier County’s disaster
relief inventory for evacuation shelters.
EverOn is a portable battery powered lighting device that provides from 30 to 500 hours
of light from one battery set, including 500 hours of a low, nightlight level light; 60 hours
of a medium, room-filling light; and 30 hours of intensely bright white light. The EverOn
is bulb free and uses the latest in Cyberlux solid-state LED lighting technology as the
lighting elements, which are 90 percent more energy efficient than conventional
incandescent flashlights.
Cyberlux has worked with Southwest Florida Emergency Management Officials to
donate disaster preparedness brochures and sample supplies of EverOn for Emergency
Preparedness Education classes for local agencies.
“The EverOn is an invaluable product for emergency preparedness – it is crucial to have
a reliable emergency lighting source when a tornado or hurricane hits and the EverOn
provides over 60 hours of comforting light,” said Dan Summers, director of Collier
County Emergency Management. “The product is lightweight, easy-to-use and is a multipurpose
lighting product invaluable during a storm.”
The LED lighting elements are packaged in a hand-held elliptical parabolic reflector
product design, providing a practical, portable emergency lighting solution for every
consumer who has experienced the unease and inconvenience of power outages caused
by natural or man-made disasters. Designed to provide homeowners with portable, longlasting,
emergency lighting during the hurricane and tornado season, the new EverOn is a
sturdy, virtually indestructible, lighting product that provides over 60 hours of
comfortable room-filling light on the medium setting and over 30 hours of intensely
bright white light on the highest setting, all in a 7 inch by 3.5 inch by 2.4 inch package.
“There really isn’t another product comparable to the EverOn Multi-purpose Emergency
Light,” said Don Evans, chief executive officer of Cyberlux. “Unfortunately, the last few
years have shown us that candles and conventional lighting sources aren’t reliable when
it comes to extended or even short-term power outages – the EverOn provides peace of
mind and handles all emergency lighting needs.”
Cyberlux is making the EverOn Multi-purpose Emergency Light available to emergency
management, consumers and disaster relief organizations under its special Disaster
Preparedness Program. Interested consumers and Emergency management groups should
visit http://www.luxsel.com to order the EverOn or call (800) 939-2925. For more
information, please contact cyblinfo@cyberlux.com.
About Cyberlux Corporation
Cyberlux Corporation (OTC Bulletin Board: CYBL) has created breakthrough LED
lighting technology that provides the most energy efficient and cost effective lighting
solutions available today for consumer, commercial and military uses. The ReliaBright
products are designed to address emergencies such as power outages or critical security
lighting needs. The Aeon products bring the newly developed, virtually heatless light into
the home for use in closets, cabinet interiors and under cabinet lighting for kitchen
counters. The Military and Homeland Security products deliver unique, covert, and
advanced visible lighting capability for threat detection, force and asset protection.
Cyberlux uses solid-state semiconductors, trademarked as its diodaltm lighting elements,
which consume 75% less energy than incandescent lighting elements and perform for
over 20 years in contrast to 750 hours for conventional bulbs. For more information,
please visit www.cyberlux.com.
Public Relations Contacts
Ronnie Welch and Kelly Cinelli, CWR Partners / 508-222-4802
ronnie@cwrpartners.com / kelly@cwrpartners.com
Investor Contact
Cyberlux Corporation / 919-474-9700
By: 123dave321
26 Apr 2006, 12:44 PM EDT
Msg. 9700 of 9700
Jump to msg. #
A writer on the German board claims he got this e-mail from MrNurse today:
The annual report has been delayed because my accountant is an idiot, does not care about deadlines and chose not to complete his work on time. There is nothing more sinister than I have an irresponsible account. He had all information since January to complete our audit and only started to work on it last week. Obviously because so much is vested in our staying on the bulletin board I have a very keen interest and I have been doing whatever I can to get this process expedited.
I have been in Bangkok working on completing the process of aquiring the 80rai for our first project here...the 800 houses or so we have announces last year....first part.
The plans already have been completed, contractors chosen, alliances formed and we are waiting to get a legal all clear.
There are other projects here and in the region that are downstream: I have chosen to cocentrate on this and another first because we own this project.
Gross revenues from the sale of the houses should be around 30, millUS. WE had announces about 100,000,000 worth of contract and I will spend the time here to deliver 100,000,000 worth of contracts.
The office has been relocated to Ft. Lauderdale. Unfortunately it was done before the phones were moved. But by the weekend the phones should be connected at the new office.
By: dollarstock
25 Apr 2006, 02:27 PM EDT
Msg. 27103 of 27107
Jump to msg. #
MY GOSH!! FOLKS JUST SAW WHO BOUGHT 8.2 MILLION SHARES
China Technology Global Corporation Signs Memorandum of Understanding with Si Chuan Ying Shan Digital Technology Co., Ltd to Acquire 49 per cent of the Shareholding
Monday April 24, 7:32 am ET
HONG KONG, April 24 /Xinhua-PRNewswire-FirstCall/ -- China Technology Global Corporation (OTC Bulletin Board: CTGLF; the ''Company''), announced the signing of a Memorandum of Understanding to acquire 49% shareholding of Si Chuan Ying Shan Digital Technology Co., Ltd (''YS Digital''). YS Digital has agreed the Company to start the due diligence for this business acquisition.
YS Digital, located in Chengdu City Sichuan Province PRC, founded in 2004, is now one of the leading disc production companies in the Southwest, China. Dr. Frank Fan, Chairman and Chief Executive Officer of China Technology Global Corporation commented: ''Read-only disc industry is a highly regulated industry by the Chinese central government in order to control problems of illegal copies. So far only 83 licenses of disc production have been granted to the Chinese enterprises by the central government in China. With recent increasing elimination on illegal copies, the Chinese central government has already suspended 14 licenses in March of 2006, reducing total licenses from 83 to 69. And moreover, it is estimated that the authority will further suspend more licenses. YS Digital is one of the companies on the government list of clean-record of no illegal copies."
Mr. Gao Song Ji, General Manager of Oriental Optical Disk Manufacture Co. Ltd. (''Oriental Disc''), one of the subsidiaries of China Merchants DiChain Group, commented: '' I am very glad to know this development. Oriental Disc is the leading DC\VCD production manufacturer in this region, and YS Digital was the only regional competitor to us. Hence, this coming acquisition should change competition into true collaboration.''
Contact:
China Technology Global Corporation
Sifie Fu
Investor Relations Manager
Tel: +852-2255-0688
Email: sifiefu@ChinaTechGlobal.com
Investor Relations Division
Email: Investors@ChinaTechGlobal.com
Website: www.ChinaTechGlobal.com
--------------------------------------------------------------------------------
Source: China Technology Global Corporation
you are stupid for answering a basher
from the website:
We are back, the Bankruptcy has been dismissed on April 19, 2006! Next Tuesday and Friday we will address some SEC issues and we will start to file all necessary 10K's and 10 Q's which where not done since 2001. The previous management indicated that they will help with the financials missing since 2001. New exciting products will be included within 1 month. New website will be on as soon as possible.
Thank you,
Mario Quenneville,
President and CEO
WHAT ABOUT THE ONYY SHARES A S S H O L E.
NEXT BIG THING:
www.xechemnigeria.org/about.htm
American Company
JAY JAY READ:
lori on Raging Bull board claims that she knows"for a fact" that the
monthly price for Nicosan treatment to be $2000.00 a month.I believe
she was referring to "industrialized,modernized nations" when she
referred to the $2000.00 figure.So there are 12 million who suffer SCD
worldwide.Considering that figure,you are looking at a mind blowing
amount of money/revenue.$24,000,000,000.00 billion a month &
$288,000,000,000.00 billion a year.Obviously not everyone will get the
medicine although I pray that they will...& in 3rd world countries the
cost will/should not be anywhere near this expensive but I believe the
average of $100 a month could be close & that is still an incredible
amount of money...$1.200,000,000.00 a month...$15,000,000,000.00 a
year,therefore I believe Xechem to be worth much much more than the
$500 million price I've been hearing.That figure is laughable & Dr.
Pandey knows it & therefore has said no way to these ridiculous offers
like he indeed should.
Good DD sunyfla, I am getting the feeling that Raging Bull is owned by MM's.
imo
This answers a lot of Questions.
Wait for THIS RUN:
http://www.bioportfolio.com/march_05/07_03_2005/firm_plans_new_drug_for.html
Xechem Pharmaceuticals, a United States registered company is currently at an advanced stage of setting up a manufacturing facility at SHESTCO. Xechem's preliminary product, Nicosan, a drug for dealing with the sickle cell ailment will be produced here and marketed within Nigeria and other regions of the world where sickle cell anaemia is endemic. Xechem and the Biotechnology Advanced Laboratory of SHESTCO are also collaborating on other projects.
This is GREAT:
By: jskibla
16 Mar 2006, 10:05 PM EST
Msg. 15443 of 15451
Jump to msg. #
Stephen Burg with SFNL
Sold 75K of SFNL Jan 20th - to buy XKEM shares? (see link)
http://finance.yahoo.com/q/it?s=sfnl.ob
PLANTATION, Fla., Jan. 25, 2005 (PRIMEZONE) -- Secured Financial Network,
Inc. (OTCBB:SFNL), a vertically integrated financial services company, has
begun trading on the Over the Counter Bulletin Board under the symbol SFNL.
It acquired its publicly traded position from 12 to 20 Plus, Inc., which
elected to become a privately held company.
Secured Financial Network provides origination of lines of credit, lending
facilities for commercial and industrial projects, and servicing of these
loan portfolios. In addition, the company provides management services for
real estate-based projects.
Stephen F. Burg, another new Director, is Chief Executive Officer of SB
Corporate Consulting, Inc., which offers corporate growth strategies for
public and private companies internationally. Earlier, Burg was Vice
President-Corporate Acquisitions for Evans Products Company, a New York
Stock Exchange-listed company with more than $2 billion in annual revenues.
Prior to that, he was Corporate Director-Acquisitions and Human Services for
Jack August Enterprises. He has served as a Director of a pharmaceutical
company, Xechem International, Inc. and its Xechem Nigeria, Inc. subsidiary,
for the past 11 years. He also serves as a consultant to a number of
growth-oriented companies, both public and private. Burg, a graduate of
Boston University, is a licensed pilot, and holds several real estate
certifications.
Shorts have covered, hopefully they are gone with news coming.
Shorts have covered, hopefully they are gone with news coming.
Press Release Source: Xechem International, Inc.
Xechem Files Orphan Drug Application with the FDA For The Anti-Sickling Compound Licensed From Virginia Commonwealth University
Tuesday March 14, 6:30 am ET
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--March 14, 2006--Xechem International, Inc. (OTC BB: XKEM - News) Xechem International announced today that it has submitted its Orphan Drug Application for the five-membered heterocyclic anti-sickling compound known as 5-HMF to the United States Food and Drug Administration (FDA).
ADVERTISEMENT
Research Shows Efficacy of 5-HMF
As reported on December 9, 2005, this promising compound has shown excellent biological activity in preliminary testing as an anti-sickling agent. This was discovered by Prof. Donald Abraham and his team of scientists from Virginia Commonwealth University (VCU), Richmond, VA in collaboration with a team of doctors and scientists at NHLBI Sickle Cell Disease Reference Laboratory at The Children's Hospital of Philadelphia (CHOP), University of Pennsylvania led by Professor Toshio Asakura. Xechem has acquired the exclusive, worldwide rights from VCU for the production, sales and marketing of 5-HMF for use in the battle against SCD.
Research has shown that the 5-HMF compound is not only a natural product with very little if any toxicity, it also appears to be an effective anti-sickling agent which has shown high affinity for hemoglobin and is very active in genetically modified transgenic (Tg) mice. Professor Abraham of VCU has characterized this compound as "the best potential antisickling agent in 30 years research to be discovered by (VCU's) research group." See Xechem's December 9, 2005 Press Release.
If granted, Orphan Drug status will afford Xechem seven years of marketing exclusivity for the drug once the drug is ultimately approved by the FDA, and will offer Xechem tax credits, filing fee waivers and certain other statutory benefits.
5-HMF Complements Xechem's Existing Arsenal for Treatment of Sickle Cell Disease
According to Xechem's Chairman and CEO, Dr. Ramesh C. Pandey, "This new compound licensed from VCU represents the latest effort undertaken by Xechem in the fight against Sickle Cell Disease (SCD), and adds to Xechem's existing arsenal of NICOSAN(TM)/HEMOXIN(TM), an all natural, phyto-pharmaceutical product that has shown enormous promise for SCD sufferers. NICOSAN(TM)/HEMOXIN(TM) has already been designated as an Orphan Drug both in the United States and in European Union countries. It was acquired under an exclusive worldwide license from the National Institute for Pharmaceutical Research and Development (NIPRD), Ministry of Health, Government of Nigeria, Between the progress we have been making in bringing NICOSAN(TM) to market, and this exciting new heterocyclic pharmaceutical agent being developed in collaboration with VCU, we expect Xechem to be front and center in eventually offering the most viable and efficacious treatments to patients suffering with SCD around the world." Dr. Pandey added that the Company intends shortly to prepare and file an Investigational New Drug (IND) Application for submission to the FDA for both HEMOXIN(TM) and 5-HMF.
About Sickle Cell Disease
Sickle Cell Disease is a genetic blood disorder caused by an abnormality in the hemoglobin molecule. Patients with this disease often produce stiff, abnormally shaped cells that do not flow freely through blood vessels, creating clogs in the vessels, which in turn cut off the flow of normal hemoglobin and oxygen to the body. In Nigeria alone, more than 25% of the population are carriers of the SCD trait and over 4.5 million Nigerians (about 5% of the population) are actually afflicted with the disease. Approximately 15 million people, mostly in sub-Saharan Africa, are believed to suffer from this disease worldwide.
You know its MM manipulation SA
XKEM
NIPRISAN - a drug for treatment of Sickle cell Anaemia
Developed by the National Institute for Pharmaceutical Research (NIPRD), Abuja.
Patent filed 1990 (Nigeria), 1997 (USA)
Patents granted by 1998 (USA and 44 countries)
US Patent No. 5,800,819
Clinical trials (1994 – 2002)
Exclusive License granted to XECHEM Inc of USA (2002) by NIPRD
to manufacture drug. (Royalty: 7.5% NS)
Manufacture started at NIPRD facilities at Abuja (Jan. 2003) pending establishment of Independent manufacturing facilities.
A successful transfer of technology made possible by:
IPR
Licensing of IPR to XECHEM (a foreign Company) to manufacture product locally.
Support by UNDP
* Other promising research results: Anti malaria; Anti-AIDS; Ulcer & Fungal agents.
Close today? .025-.035
To MM's SHORTING XKEM,
You will lose this one with your illegal shorting,
this company is REAL, with a REAL product.
I hope you don't lose your health shorting this company.
OT:
XKEM - NEWS Xechem Files Orphan Drug Application with the FDA For The Anti-Sickling Compound Licensed From Virginia Commonwealth University
Mar 14, 2006 6:30:00 AM
Copyright Business Wire 2006
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--March 14, 2006--
Xechem International, Inc. (OTC BB: XKEM) Xechem International announced today that it has submitted its Orphan Drug Application for the five-membered heterocyclic anti-sickling compound known as 5-HMF to the United States Food and Drug Administration (FDA).
Research Shows Efficacy of 5-HMF
As reported on December 9, 2005, this promising compound has shown excellent biological activity in preliminary testing as an anti-sickling agent. This was discovered by Prof. Donald Abraham and his team of scientists from Virginia Commonwealth University (VCU), Richmond, VA in collaboration with a team of doctors and scientists at NHLBI Sickle Cell Disease Reference Laboratory at The Children's Hospital of Philadelphia (CHOP), University of Pennsylvania led by Professor Toshio Asakura. Xechem has acquired the exclusive, worldwide rights from VCU for the production, sales and marketing of 5-HMF for use in the battle against SCD.
Research has shown that the 5-HMF compound is not only a natural product with very little if any toxicity, it also appears to be an effective anti-sickling agent which has shown high affinity for hemoglobin and is very active in genetically modified transgenic (Tg) mice. Professor Abraham of VCU has characterized this compound as "the best potential antisickling agent in 30 years research to be discovered by (VCU's) research group." See Xechem's December 9, 2005 Press Release.
If granted, Orphan Drug status will afford Xechem seven years of marketing exclusivity for the drug once the drug is ultimately approved by the FDA, and will offer Xechem tax credits, filing fee waivers and certain other statutory benefits.
5-HMF Complements Xechem's Existing Arsenal for Treatment of Sickle Cell Disease
According to Xechem's Chairman and CEO, Dr. Ramesh C. Pandey, "This new compound licensed from VCU represents the latest effort undertaken by Xechem in the fight against Sickle Cell Disease (SCD), and adds to Xechem's existing arsenal of NICOSAN(TM)/HEMOXIN(TM), an all natural, phyto-pharmaceutical product that has shown enormous promise for SCD sufferers. NICOSAN(TM)/HEMOXIN(TM) has already been designated as an Orphan Drug both in the United States and in European Union countries. It was acquired under an exclusive worldwide license from the National Institute for Pharmaceutical Research and Development (NIPRD), Ministry of Health, Government of Nigeria, Between the progress we have been making in bringing NICOSAN(TM) to market, and this exciting new heterocyclic pharmaceutical agent being developed in collaboration with VCU, we expect Xechem to be front and center in eventually offering the most viable and efficacious treatments to patients suffering with SCD around the world." Dr. Pandey added that the Company intends shortly to prepare and file an Investigational New Drug (IND) Application for submission to the FDA for both HEMOXIN(TM) and 5-HMF.
About Sickle Cell Disease
Sickle Cell Disease is a genetic blood disorder caused by an abnormality in the hemoglobin molecule. Patients with this disease often produce stiff, abnormally shaped cells that do not flow freely through blood vessels, creating clogs in the vessels, which in turn cut off the flow of normal hemoglobin and oxygen to the body. In Nigeria alone, more than 25% of the population are carriers of the SCD trait and over 4.5 million Nigerians (about 5% of the population) are actually afflicted with the disease. Approximately 15 million people, mostly in sub-Saharan Africa, are believed to suffer from this disease worldwide.
About Xechem
Xechem International, Inc. is a development stage biopharmaceutical company focusing on anticancer, antiviral (including AIDS), antifungal, Sickle Cell Disease (SCD), antimalarial and antibacterial products from natural sources, including microbial and marine organisms as well as the development of phyto-pharmaceuticals and other proprietary technologies, including those used in the treatment of orphan diseases. Xechem's mission is to bring relief to the millions of people who suffer from these diseases. Its primary attention and resources are currently being directed toward the development and commercial launch of the phyto-pharmaceutical NICOSAN(TM)/HEMOXIN(TM), which has shown efficacy in the treatment of SCD.
Heavy accumulation today!!
By: pipster_2
06 Mar 2006, 11:05 AM EST
Msg. 8995 of 8995
Jump to msg. #
I went to the new offices of This Group on the 21st of Feb, it is in the State Tower a very palacial building close to the River in Bangkok.
The office was empty but there were furniture and things arriving while I was there, I met Sutida who did introduce me to people that were working on SWKJ and BUZZ,the SWKJ group was 6 people 4 Thai/Asian and 2 Others possibly American. The Buzz group 4 people were all Thai/Asian.
During my meeting there were a number of interruptions from deliveries and phone calls, this made it a little difficult to concentrate however, I did leave with confidence that there were real things happening there.
hit .03